ArticleGeroScience2026
Association between whole-blood NAD+ concentration and frailty in community-dwelling older adults: the Itabashi Longitudinal Study on Aging.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nicotinamide adenine dinucleotide (NAD⁺) is central to energy metabolism, redox reactions, and cellular signaling. However, human evidence linking circulating NAD⁺ concentrations to frailty remains limited. We examined the association of whole-blood NAD⁺ concentration with frailty in community-dwelling older adults. This cross-sectional analysis included community-dwelling adults aged ≥ 65 years from the 2025 Itabashi Longitudinal Study on Aging. Frailty was assessed using the revised Japanese Cardiovascular Health Study Criteria. Multivariable linear and logistic regression models adjusted for age, sex, and fasting time assessed the association. Restricted cubic spline, Firth penalized-likelihood logistic regression, and hematological sensitivity analyses were also performed. Among 529 participants (54.3% women), 32 (6.0%) had frailty. Median whole-blood NAD⁺ concentration was lower among participants with frailty than among those without frailty (24.00 vs. 25.00 µmol/L; P = 0.007). After adjustment for age, sex, and fasting time, higher whole-blood NAD⁺ concentration was associated with lower odds of frailty (OR per 1 µmol/L increase, 0.871; 95% CI, 0.780-0.970; P = 0.013). Restricted cubic spline analysis showed no clear evidence of nonlinearity. The association persisted after broader covariate adjustment using the Firth regression (OR, 0.880; 95% CI, 0.782-0.986) but was attenuated after additional adjustment for hematocrit (OR, 0.911; 95% CI, 0.800-1.034). Lower whole-blood NAD⁺ concentration was associated with frailty in community-dwelling older adults. Attenuation after hematocrit adjustment suggests that blood cell composition may partly explain this association. Further studies using cell- and tissue-specific measurements are needed to clarify the relationship between NAD⁺ metabolism and frailty.
Indexed as
Identifiers
42744962What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.